Dishman Carbogen Amcis Ltd
NSE:DCAL
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
136.5
273.5
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Dishman Carbogen Amcis Ltd
Dishman Carbogen Amcis Ltd
Total Equity
Dishman Carbogen Amcis Ltd
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Dishman Carbogen Amcis Ltd
NSE:DCAL
|
Total Equity
₹56.3B
|
CAGR 3-Years
0%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
|
Divi's Laboratories Ltd
NSE:DIVISLAB
|
Total Equity
₹135.7B
|
CAGR 3-Years
13%
|
CAGR 5-Years
50%
|
CAGR 10-Years
N/A
|
|
|
Suven Life Sciences Ltd
NSE:SUVEN
|
Total Equity
₹1.9B
|
CAGR 3-Years
57%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
N/A
|
|
|
Syngene International Ltd
NSE:SYNGENE
|
Total Equity
₹44B
|
CAGR 3-Years
13%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
|
Tarsons Products Ltd
NSE:TARSONS
|
Total Equity
₹6.1B
|
CAGR 3-Years
36%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
I
|
Innova Captab Ltd
NSE:INNOVACAP
|
Total Equity
₹8.3B
|
CAGR 3-Years
79%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Dishman Carbogen Amcis Ltd
Glance View
Dishman Carbogen Amcis Ltd. is a manufacturing company, which engages in the provision of outsourcing services for the pharmaceutical industry. The company is headquartered in Ahmedabad, Gujarat. The company went IPO on 2017-09-21. The firm's segments include CRAMS and Vitamin - D, Bulk Drugs, Quats, Specialty Chemicals and traded goods. The firm assists pharma companies through various stages of drug development from process research and development to late-stage clinical and commercial manufacturing facilities, along with the supply of active pharmaceutical ingredients (APIs) and intermediates. The firm has manufacturing and research facilities in India, Switzerland, France, Netherlands, United Kingdom and China. The firm's subsidiaries include CARBOGEN AMCIS (Shanghai) Co. Ltd, Dishman Infrastructure Ltd., Dishman Carbogen Amcis (Singapore) Pte. Ltd., CARBOGEN AMCIS Holding AG and Dishman Biotech Ltd.
See Also
What is Dishman Carbogen Amcis Ltd's Total Equity?
Total Equity
56.3B
INR
Based on the financial report for Jun 30, 2024, Dishman Carbogen Amcis Ltd's Total Equity amounts to 56.3B INR.
What is Dishman Carbogen Amcis Ltd's Total Equity growth rate?
Total Equity CAGR 5Y
1%
Over the last year, the Total Equity growth was -3%.
You don't have any saved screeners yet
